Q2 2025 Key Performance Highlights - Funded Accounts reached 363 million, a 14% year-over-year increase[12] - Assets Under Administration (AUA) totaled $175 billion, up 54% year-over-year[12] - Net Contribution amounted to $210 million, reflecting a 26% year-over-year growth[12] - Adjusted EBITDA was $72 million, a 31% increase compared to the previous year[12] Business Strategy and Product Updates - The company is focused on four strategic pillars: Trading, Investing, Wealth Management, and Neo-Banking, to drive global expansion and product localization[15, 16, 17, 18, 19] - New product launches include 24/5 trading for U S equities and futures, new Smart Portfolios with Franklin Templeton, French savings products, and the eToro Card now available in multiple E U markets[22, 23, 26, 27] - The company is expanding its crypto offering in the U S, providing access to over 100 tokens[28] - The company launched Tori, an AI analyst providing personalized investment insights[29] Financial Performance Details - Net Trading Contribution from Equities, Commodities, and Currencies was $114042 thousand for the three months ended June 30, 2025[123] - Revenue from Cryptoassets was $1914792 thousand for the three months ended June 30, 2025[123] - Net income for Q2 2025 was $30185 thousand, which includes $15 million of IPO and other related costs[110, 130]

Liquidia Corporation 2Q2025 Financial Results & Corporate Update August 12, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3 Rapid adoption over last 11 weeks! As of August 8, 2025 This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements ...

Commercial Performance - 2Q 2025 net product revenues reached $18.1 million, a 6.2% increase compared to $17.0 million in the same quarter of 2024 [16, 58] - Total 1H 2025 net product revenue was $35.5 million, up from $34.9 million during the 1H of 2024 [16] Pipeline Progress - LOTIS-7 data showed a 93.3% ORR (Overall Response Rate) and an 86.7% CR (Complete Response) rate across 30 efficacy evaluable patients when ZYNLONTA was combined with glofitamab [16, 53] - Updated MZL IIT data presented at ICML demonstrate an 85% ORR and a 69% CR rate [16] - LOTIS-5 is on track to reach pre-specified PFS (Progression-Free Survival) events by the end of 2025 [16] Corporate Update - The company secured $100 million in private placement, extending the expected cash runway into 2028 [16] - A strategic prioritization was implemented, resulting in a 30% reduction in force and one-time charges of $13.1 million, including $6.7 million in employee severance and $6.4 million in non-cash impairment of assets related to the UK facility closure [16] - The company's cash balance was $264.6 million as of June 30, 2025 [16, 58] LOTIS-7 Trial Safety - In the LOTIS-7 Phase 1b trial, 56.1% of patients experienced Grade 3/4 TEAEs (Treatment-Emergent Adverse Events) [47] - Cytokine Release Syndrome (CRS) of any grade was observed in 39% of patients [49] - ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) of any grade was observed in 7.3% of patients [49] ZYNLONTA Market Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL (Diffuse Large B-Cell Lymphoma) and indolent lymphomas [21, 22]

Financial Performance - Net sales decreased to $39245 thousand in Q2 2025 from $54793 thousand in Q2 2024 [23] - Adjusted Gross Profit decreased to $7531 thousand in Q2 2025 from $13349 thousand in Q2 2024 [23] - Adjusted Gross Profit Margin decreased to 192% of net sales in Q2 2025 from 244% in Q2 2024 [23] - Adjusted SG&A increased to 250% of net sales in Q2 2025 from 212% in Q2 2024, while the actual expense decreased to $9803 thousand from $11624 thousand [23] - Adjusted EBITDA decreased to $(2272) thousand in Q2 2025 from $1725 thousand in Q2 2024 [23] Strategic Initiatives and Restructuring - A new restructuring plan was initiated to optimize the product portfolio, distribution center, and manufacturing footprint [13, 16] - The company anticipates over $3 million in estimated annual cost savings from the restructuring plan, along with improvements in working capital [16] - The company is focused on higher-margin proprietary brands by eliminating underperforming brands [16] - The company expects improved Adjusted Gross Profit Margin and reduced year-over-year Adjusted SG&A expense for full year 2025 [20] Liquidity and Debt - Cash balance as of June 30, 2025, was $110 million [30] - Liquidity, defined as cash plus available borrowing capacity, was $200 million as of June 30, 2025 [30] - Free Cash Flow for the three months ended June 30, 2025, was $14 million [30] - Total debt outstanding as of June 30, 2025, was $1226 million, with net debt at $1116 million [30]

Financial Performance - AUCATZYL net product sales reached $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025[8] - The company's cash, cash equivalents, and marketable securities totaled $454.3 million as of June 30, 2025[24] - Cost of sales for Q2 2025 was $24.445 million[24] - Research and development expenses, net for Q2 2025 were $27.430 million[24] - Selling, general, and administrative expenses for Q2 2025 were $30.265 million[24] - Loss from operations for Q2 2025 was $61.217 million[24] - Total comprehensive loss for Q2 2025 was $28.949 million[24] AUCATZYL Commercialization and Market Access - 46 treatment centers are authorized for AUCATZYL as of August 12, 2025[8] - Over 90% of total U S medical lives are covered for AUCATZYL[10] Obe-cel Clinical Data and Development - At 3 years of follow-up, 38.4% of responders remain in remission without subsequent treatment[14, 15] - The probability of remaining in remission after 24 months was 54.1% censoring for consolidative SCT[17] - At 24 months, overall survival probability was 46.0%[19] Upcoming Milestones - Initial data from PY01 trial in pediatric ALL is expected in H2 2025[27]

Financial Performance & Growth - TAT Technologies reported Q2 2025 revenue of $43.1 million, an 18% increase year-over-year compared to $36.5 million in Q2 2024 [41] - Gross profit for Q2 2025 was $10.8 million, a 36% increase from $8.0 million in Q2 2024 [41] - Operating income increased by 62% to $4.4 million in Q2 2025, compared to $2.7 million in Q2 2024 [41] - Adjusted EBITDA for Q2 2025 was $6.1 million, a 39% increase from $4.3 million in Q2 2024, with an Adjusted EBITDA Margin of 14.0% [41] - The company's backlog reached $524 million in Q2 2025 [23] Revenue Diversification - Heat Exchange revenue was $17.7 million in Q2 2025, representing a 12% year-over-year increase [97] - APU revenue was $11.5 million in Q2 2025, a 7% increase year-over-year [97] - Trading & Leasing revenue experienced significant growth, reaching $5.9 million in Q2 2025, a 201% increase compared to Q2 2024 [97] Balance Sheet - Shareholder's equity stood at $165.8 million in Q2 2025 [106] - Total assets amounted to $213.6 million in Q2 2025 [106] - Operating working capital was $93.1 million in Q2 2025 [106]

Anaphylm (Epinephrine) Sublingual Film - FDA accepted the NDA for Anaphylm in Q2 2025, with a PDUFA date scheduled for January 31, 2026[8] - The company is preparing for a U S launch of Anaphylm in Q1 2026, pending FDA approval[8] - A pediatric study showed that 12 mg Anaphylm administration demonstrated comparable PK curves in adult and pediatric subjects, with no statistical differences between PK parameters[16] - Pharmacodynamic (PD) outcomes in the pediatric study showed a positive inflection for Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) after Anaphylm exposure[25] Financial Performance and Outlook - As of June 30, 2025, the company had a cash balance of approximately $60.5 million[8] - The company projects its cash runway into 2026[8] - The company is guiding for total revenues of approximately $44-$50 million for 2025[34] - The company anticipates a Non-GAAP adjusted EBITDA loss of approximately $47-$51 million for 2025[34] Manufacturing Operations - Manufacturing operations continue to generate cash[30] - Doses shipped in Q2 2025 were 37204 (thousands)[31]

Investment Highlights - Bicara Therapeutics is advancing ficerafusp alfa (FICERA), a bifunctional EGFR-directed antibody x TGF-β ligand trap, designed to enable tumor penetration by breaking barriers in the tumor microenvironment to drive deep and durable responses[8, 125] - FICERA + pembro offers a potential new 1L therapy for HPV-negative R/M HNSCC, with the FORTIFI-HN01 Ph 2/3 trial ongoing and enrolling[8, 125] - The company has a robust financial position with approximately $437 million in cash and equivalents[8, 125] Clinical Trial & Market Opportunity - There is a significant market opportunity with approximately 23,000 cases of R/M HNSCC annually in the U S, and a significant unmet need for better treatment options (13% 5yr survival)[8, 33, 125] - In a Ph 1b trial of FICERA + Pembrolizumab in HPV-neg, CPS≥1 1L R/M HNSCC, the confirmed ORR was 54% (15/28)[60, 75] - The same trial showed a median PFS of 9 9 months and a median OS of 21 3 months, with a 2-year OS rate of 46%[66, 72, 75] - The median DOR was 21 7 months, with DOR rates of 79% at 6 months, 65% at 12 months, and 57% at 18 months[69, 75] Expansion Opportunities - The company is expanding into other squamous cell carcinomas and solid tumors, with encouraging clinical activity observed in Ph 1b expansion cohorts to date[8, 125] - In 2L+ cutaneous squamous cell carcinoma (cSCC), FICERA monotherapy showed an ORR of 30% (7/23) and a mPFS of 7 0 months in PD-1-refractory patients[114] - In 2L+ squamous cancer of the anal canal (SCAC), FICERA + pembro showed a 25% ORR (7/28) and a 12-month PFS rate of 40 7%[118]

Key Highlights & Growth - Pony AI produced over 200 Gen-7 vehicles as of August 11, 2025 [7] - The company aims to produce over 1,000 vehicles by the end of 2025 [7, 22] - Registered user growth increased by 136% year-over-year from 2Q24 to 2Q25 [7, 32] - Total revenue grew by 76% in 2Q25 [7] - Fare-charging revenue experienced a growth of over 300% in 2Q25 [7, 35, 70] Commercialization & Operations - Pony AI is the only company with fully driverless commercial licenses in all four Tier-1 cities in China (Beijing, Shanghai, Guangzhou, Shenzhen) [20, 31] - Robotaxis receive approximately 15 average daily orders [20] - Accumulated autonomous driving kilometers reached 488 million+ as of June 30, 2025 [36] - Accumulated autonomous driverless kilometers reached 87 million+ as of June 30, 2025 [36] Financial Performance - Robotaxi services revenue increased by 1578% from $06 million in 2Q24 to $15 million in 2Q25 [65] - Total revenue increased by 9018% from $122 million in 2Q24 to $104 million in 2Q25 [69]

Financial Performance & Growth - Harrow expects 2025 revenue to be more than $280 million[9] - In Q2 2025, Adjusted EBITDA was $17006 thousand[16] - Harrow had $52963 thousand in cash and cash equivalents as of June 30, 2025[17] Product Portfolio & Market Position - VEVYE showed 66% Q/o/Q Rx volume growth[10, 34] - VEVYE captured 78% of the total DED market in Q2 2025, an increase of 26% from Q1 2025[39] - IHEEZO experienced 25% growth in unit demand in Q2 2025 vs Q1 2025[10] - TRIESENCE showed 32% growth in Q2 2025 vs Q1 2025, with Q4 2025 expansion to a new market[10] Strategic Initiatives & Acquisitions - Harrow expanded the VAFA program capacity with a strategic alliance with Apollo Care in August 2025[9] - Harrow acquired the exclusive U S rights to Samsung Bioepis ophthalmology biosimilars pipeline, including BYOOVIZ (Lucentis) & OPUVIZ (Eylea) in July 2025[9] - Harrow acquired the exclusive U S commercial rights for BYQLOVI in June 2025, planning a launch in Q1 2026[9, 46]